NeuBase Therapeutics

54 articles about NeuBase Therapeutics

• NeuBase Therapeutics Demonstrates Functional Rescue in Myotonic Dystrophy Type 1 Model and Allele-Selective Inhibition of KRAS Mutations to Inhibit Tumor Growth

  6/8/2021

  NeuBase Therapeutics, Inc. (Nasdaq: NBSE) ("NeuBase" or the "Company"), a biotechnology company accelerating the genetic revolution using a new class of precision genetic medicines, today announced positive new data and program updates for its development pipeline of PATrOL-enabled genetic medicines.

• NeuBase Therapeutics Announces Speakers for Virtual R&D Day Taking Place on June 8th

  6/2/2021

  NeuBase Therapeutics, Inc. (Nasdaq: NBSE) ("NeuBase" or the "Company"), a biotechnology company accelerating the genetic revolution using a new class of precision genetic medicines, today announced that it will host a virtual R&D day for investors and analysts on Tuesday, June 8, 2021 at 12:30 p.m. EDT.

• NeuBase Therapeutics Appoints Dr. Kia Motesharei Chief Business and Strategy Officer

  5/25/2021

  Expansion of management team continues with addition of an industry leader with deep experience in business development, licensing, and strategy in the life-science industry

• 

  BioSpace Movers & Shakers, May 21

  5/21/2021

  Biopharma and life sciences companies strengthen their leadership teams and board with these Movers & Shakers.

• NeuBase Therapeutics Appoints Dr. Sandra Rojas-Caro Chief Medical Officer

  5/20/2021

  NeuBase Therapeutics, Inc. (Nasdaq: NBSE) ("NeuBase" or the "Company"), a biotechnology company accelerating the genetic revolution using a new class of precision genetic medicines, today announced the appointment of Sandra Rojas-Caro, M.D., as Chief Medical Officer, effective May 24, 2021. With more than 20 years of drug development experience across all phases of drug development,

• NeuBase Therapeutics to Participate in Upcoming Investor Conferences in May 2021

  5/14/2021

  NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase”), a biotechnology company accelerating the genetic revolution with a new class of precision genetic medicines, announced today that Dietrich A. Stephan, Ph.D., Chief Executive Officer of NeuBase, will participate in a virtual fireside chat at the RBC Capital Markets Virtual Global Healthcare Conference,

• NeuBase Therapeutics Reports Financial Results for the Second Quarter of Fiscal Year 2021

  5/13/2021

  NeuBase Therapeutics, Inc. (Nasdaq: NBSE) ("NeuBase" or the "Company"), a biotechnology company accelerating the genetic revolution using a new class of precision genetic medicines, today reported its financial results for the three- and six-month periods ended March 31, 2021.

• NeuBase Therapeutics to Present at the B. Riley Securities’ Virtual Neuroscience Conference

  4/27/2021

  NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase”), a biotechnology company accelerating the genetic revolution with a new class of precision genetic medicines, announced today that Dietrich A. Stephan, Ph.D., Chief Executive Officer of NeuBase, will present a corporate overview at the B. Riley Securities’ Virtual Neuroscience Conference being held on April 28 - 29.

• NeuBase Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares - Apr 26, 2021

  4/26/2021

  NeuBase Therapeutics, Inc., a biotechnology company accelerating the genetic revolution with a new class of precision genetic medicines, announced the closing of its previously announced underwritten public offering of 9,200,000 shares of its common stock, at a price to the public of $5.00 per share, generating gross proceeds of $46.0 million before deducting the underwriting discounts and commissions and offering expenses payable by NeuBase.

• NeuBase Therapeutics Announces Pricing of $40 Million Public Offering of Common Stock

  4/22/2021

  NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase”), a biotechnology company accelerating the genetic revolution with a new class of precision genetic medicines, announced today the pricing of an underwritten public offering of 8,000,000 shares of its common stock, at a price to the public of $5.00 per share.

• NeuBase Therapeutics Announces Proposed Public Offering of Common Stock

  4/21/2021

  NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase”), a biotechnology company accelerating the genetic revolution with a new class of precision genetic medicines, announced today that it has commenced an underwritten public offering of shares of common stock.

• NeuBase Therapeutics to Host a Virtual R&D Day on June 8th to Provide Updates on the Drug Development Pipeline Targeting Genetic Diseases

  4/8/2021

  NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology company accelerating the genetic revolution with a new class of precision genetic medicines, announced today that it will host a virtual R&D day for investors and analysts on Tuesday, June 8, 2021, from 12:30 p.m. to 2:30 p.m. EDT.

• NeuBase Therapeutics to Present at the 2021 Muscular Dystrophy Association Virtual Clinical & Scientific Conference

  3/16/2021

  NeuBase Therapeutics, Inc., a biotechnology company accelerating the genetic revolution using a new class of synthetic medicines, announced an oral presentation at the 2021 Muscular Dystrophy Association Virtual Clinical & Scientific Conference being held from March 15-18, 2021.

• NeuBase Therapeutics to Present at Upcoming Investor Conferences in March 2021

  3/9/2021

  NeuBase Therapeutics, Inc. (NASDAQ: NBSE) (“NeuBase” or the “Company”), a biotechnology company accelerating the genetic revolution using a new class of synthetic medicines, announced today that Dietrich A. Stephan, Ph.D., Chief Executive Officer of NeuBase, will present a corporate overview at the H.C. Wainwright Global Life Sciences Conference and at the Oppenheimer 31 st Annual Healthcare Conference.